The combination of NF-κB inhibitor and JNK inhibitor might provide a better treatment for T-ALL leukemia by synergistically killing LSPCs while simultaneously preventing the death of normal HPCs. The gene discussed is NFKB1; the disease is acute lymphoblastic leukemia.